

PRODUCT INFORMATION




Risperidone E-Oxime

Item No. 22156

CAS Registry No.: 691007-09-7
Formal Name: 3-[2-[4-[(E)-(2,4-difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

MF: C₂₃H₂₈F₂N₄O₂
FW: 430.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Risperidone E-oxime is supplied as a solid. Risperidone E-oxime is slightly soluble in chloroform and methanol.

Description

Risperidone E-oxime is a potential impurity found in commercial preparations of risperidone.^{1,2} Risperidone (Item No. 16329) is a longer-acting benzisoxazole derivative used for treating schizophrenia, and also the psychotic, affective, or behavioral symptoms associated with other disorders.^{3,4} This second-generation antipsychotic was designed to antagonize both D₂ and 5-HT_{2A} receptors.^{5,6} It has little effect on cholinergic and β-adrenergic receptors but does affect α₂-adrenergic and histamine H₁ receptors.^{5,6}

References

1. Bharathi, C., Chary, D.K., Kumar, M.S., *et al.* Identification, isolation and characterization of potential degradation product in risperidone tablets. *J. Pharm. Biomed. Anal.* **46(1)**, 165-169 (2008).
2. Nejedly, T., Pilarova, P., Kastner, P., *et al.* Development and validation of rapid UHPLC method for determination of risperidone and its impurities in bulk powder and tablets. *Int. J. Res. Pharm. Chem.* **4(2)**, 261-266 (2014).
3. Colpaert, F.C. Discovering risperidone: The LSD model of psychopathology. *Nat. Rev. Drug Discovery* **2**, 315-320 (2003).
4. Rainer, M.K. Risperidone long-acting injection: A review of its long term safety and efficacy. *Neuropsychiatr. Dis. Treat.* **4(5)**, 919-927 (2008).
5. Fujimuro, M., Sawada, H., and Yokosawa, H. Production and characterization of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins. *FEBS Letters* **349(2)**, 173-180 (1994).
6. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., *et al.* Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology* **14(2)**, 87-96 (1996).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM